156 related articles for article (PubMed ID: 31551171)
1. Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.
Ebisawa K; Masamoto Y; Koya J; Shimura A; Shinozaki-Ushiku A; Toyama K; Nakazaki K; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e602-e604. PubMed ID: 31551171
[No Abstract] [Full Text] [Related]
2. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
5. Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.
Li J; Sim J; Leung AYH; Kwong YL
Ann Hematol; 2018 Mar; 97(3):551-554. PubMed ID: 29198035
[No Abstract] [Full Text] [Related]
6. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
[No Abstract] [Full Text] [Related]
7. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.
Belia M; Chatzidimitriou C; Rondogianni P; Petsa P; Efstathopoulou M; Konstantinou E; Arapaki M; Asimakopoulos J; Plata E; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP
Hematol Oncol; 2021 Apr; 39(2):258-262. PubMed ID: 32905619
[No Abstract] [Full Text] [Related]
8. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
[No Abstract] [Full Text] [Related]
10. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
13. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
Fernández KS; Mavers M; Marks LJ; Agarwal R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
[No Abstract] [Full Text] [Related]
16. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
17. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
Garciaz S; Loschi M; De Masson A; Biard L; Mercier M; Tomowiak C; Delage J; Labussiere-Wallet H; Sibon D; Cassuto O; Borel C; Cornillon J; Nimubona S; Charbonnier A; Brice P; Socié G; Bouabdallah R; de Latour RP; de Fontbrune FS
Leuk Lymphoma; 2019 Nov; 60(11):2802-2805. PubMed ID: 31014144
[No Abstract] [Full Text] [Related]
19. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
20. Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement.
Mociková H; Malikova H; Holesta M; Elturki A; Campr V; Kozak T
Am J Case Rep; 2020 Mar; 21():e921657. PubMed ID: 32170052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]